A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India

Sponsor
Bristol-Myers Squibb
Study ID
NCT07459543
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to assess the safety and tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in unresectable or metastatic melanoma participants in India.

Key Dates

First listed
Mar 9, 2026
Start date
Nov 15, 2026
Status verified
Jul 2026
Primary completion
May 26, 2029
Completion
May 28, 2029

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Administration of Nivolumab + Relatlimab Fixed-Dose Combination (FDC)

Primary Outcome Measure

Incidence of adverse events (AEs) [ Time Frame: Up to 30 weeks ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Find similar trials

Nationwide
Melanoma trialsOncology trialsSkin cancer trialsDermatology trials

Related Studies